Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry and Biodistribution of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
NCT05951816Phase 1Recruiting
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Technetium Tc 99m-p5+14 in systemic amyloidosis (2 arms), sponsored by University of Tennessee Graduate School of Medicine. Primary endpoint: Whole body effective dosimetry measurement at 8 days. Started Sep 2023; status: recruiting.
02
Drugs
Technetium Tc 99m-p5+14
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT05951816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951816.